Ascentage Pharma Group Internat (AAPG) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $17.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1... Read more
Hold if already holding. Not a fresh buy at $17.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Mixed signals. Hold existing position. Score 6.5/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-03Recent Developments — Ascentage Pharma Group Internat
Latest news
- NEWS AAPG Reiterates by BTIG -- Price Target Maintained at $48 - GuruFocus — GuruFocus neutral
- NEWS BTIG Research Reaffirms "Buy" Rating for Ascentage Pharma Group International (NASDAQ:AAPG) - MarketBeat — MarketBeat positive
- NEWS BTIG reiterates Ascentage Pharma stock rating citing trial readouts By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? - MarketBeat — MarketBeat negative
- NEWS Ascentage Highlights Tumor Response Data in Pediatric Cancer Study — benzinga Jun 1, 2026 positive
Generated 2026-06-03T21:06:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·3 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Mixed signals. Hold existing position. Target $41.65 (+132.9%), stop $16.88 (−5.9%), A.R:R 10.5:1. Score 6.5/10, moderate confidence.
Take-profit target: $41.65 (+133.1% upside). Target $41.65 (+132.9%), stop $16.88 (−5.9%), A.R:R 10.5:1. Stop-loss: $16.88.
Leverage penalty (D/E 1.5): -0.5; Negative momentum; Below 200-MA, MA slope -8.8%/30d (confirmed downtrend).
Ascentage Pharma Group Internat trades at a P/E of N/A (forward -15.4). TrendMatrix value score: 8.7/10. Verdict: Hold.
12 analysts cover AAPG with a consensus score of 4.3/5. Average price target: $48.
What does Ascentage Pharma Group Internat do?Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic...
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.